Phase IIa trial to evaluate the pharmacokinetic response to bactericidal/permeability-increasing protein (rBPI21 [opebacan]) for the treatment of patients with burn injury
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2008
At a glance
- Drugs Opebacan (Primary)
- Indications Bacterial infections; Wound infections
- Focus Pharmacokinetics
- 02 Jun 2008 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
- 05 Jul 2007 New trial record.